Navigation Links
Resveratrol may be useful tool for reducing body fat
Date:3/4/2011

This release is available in Spanish.

For her thesis entitled cido Linoleico Conjugado y Resvetratrol: efecto de estos ingredientes funcionales sobre el metabolismo de los triglicridos y la adiposidad (Conjugated Linoleic Acid and Resveratrol: the effect of these functional ingredients on the metabolism of triglycerides and adiposity), Nutrition and Obesity research team member at the University of the Basque Country (UPV/EHU), Ms Arrate Lasa, studied the fat-reducing effect of CLA and resveratrol.

Obesity is a very common illness in developed countries, there being more than 1,000 million overweight persons currently in the world, of which more than 300 million suffer from obesity. This illness brings with it other, associated conditions that result in a significant increase in the morbi-mortality of these persons.

Current strategies for its treatment are various and one field of great interest is what is known as functional ingredients. These are compounds that appear in certain foods and that enhance specific corporal functions, promoting health and reducing risk of diseases.

Fat reduction with functional ingredients

Conjugated Linoleic Acid (CLA) and resveratrol are two functional ingredients that, in various experiments on living beings and in vitro, have proved to have a fat-reducing effect. On the one hand, the properties attributed to CLA indicate that it prevents weight gain and the accumulation of body fat, through inhibiting the synthesis of fat and increasing the oxidation of fatty acids. However, its effects when applied in a hypocaloric diet for the treatment of obesity are unknown. On the other, it is known that resveratrol has hypolipemiant properties, but its effect on the use of accumulated fat has not been extensively analysed.

Thus, this thesis shows, on the one hand, the results obtained after treatment with CLA in hamsters subjected to energy restriction and, on the other, the effect of resveratrol on accumulated fat and lipolytic activity in cell cultures of adipocytes of murinae and humans. The results obtained show that CLA does not foment weight or body fat loss, induced by an energy restriction diet. Neither does it induce greater lipolysis, nor improvement in serum parameters, in glucose homeostasis or insulin function to any greater extent than with the slimming diet itself. On the contrary, resveratrol reduces the accumulation of triglycerides, in part by activation of lipolysis, in both the adipocytes of mice and of humans.

For all these reasons, it can be concluded that, while CLA may not be a molecule useful in treating obesity, when resveratrol is included in hypocaloric diet, it could well be a useful tool for reducing body fat. More studies are required regarding this latter molecule, firstly to describe other effects of resveratrol and its activating mechanisms, as well as the possible adverse effects and toxicity; secondly studies amongst humans confirm the previously observed effects.


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. Resveratrol prevents fat accumulation in livers of alcoholic mice
2. Resveratrol, red wine compound linked to health, also found in dark chocolate and cocoa
3. Study on effects of resveratrol and quercetin on inflammation and insulin resistance
4. Longevinex exerts greater influence over genes than resveratrol
5. Longevinex exhibits L-shaped safety curve for first time in resveratrol biology
6. Grape ingredient resveratrol increases beneficial fat hormone
7. Linking Proteins, Wires, Dots, and Molecules into Useful Devices
8. The sky is not falling: Pollution in eastern China cuts light, useful rainfall
9. Virus may chauffeur useful packages into plants
10. Genetically modified cell procedure may prove useful in treating kidney failure
11. Scientists reprogram mouse fat cells into clinically useful stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of ... reported its financial results for the fourth quarter and full ... 4Q16 record quarterly net sales of $1.13 billion, ... 4Q16 EMEA-APAC segment net sales ... Americas net sales increased 2.5%, or down 0.9% on an ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology: